Navigation Links
Novelos Therapeutics Provides Product Pipeline Update
Date:5/16/2013

MADISON, Wis., May 16, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today provided an update on its product pipeline, including I-124-CLR1404 (LIGHT) positron emission tomography (PET) imaging agent for solid tumor indications, I-131-CLR1404 (HOT) cancer-targeted molecular radiotherapeutic for advanced solid tumors and CLR1502 (GLOW2) optical imaging agent for intraoperative tumor margin illumination in real-time and non-invasive tumor imaging.

"We are excited to be advancing multiple product opportunities aimed at significant unmet needs, all based on Novelos' proprietary cancer-targeted delivery platform," said Harry Palmin, President and CEO of Novelos.  "Our development plan is centered on advancing compounds that we expect to most rapidly achieve significant development milestones.  Both LIGHT and GLOW2, subject to additional funding, are expected to reach such milestones by the end of 2014."

LIGHT is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent.  LIGHT Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.  These trials have demonstrated initial proof-of-concept in multiple tumor types, including primary and metastatic brain cancer.  Novelos expects to start a LIGHT Phase 2 imaging trial in brain cancer at the beginning of 2014 and, subject to additional funding, complete the trial by the end of 2014.  This trial will compare LIGHT imaging of glioma with standard of care based on pathology confirmation in approximately 30 patients.

"In early PET imaging trials with I-124-CLR1404 (LIGHT) in primary and metastatic brain cancer patients, we have observed high tumor-to-background ratios," said Lance Hall , M.D., Assistant Professor of Radiology at the University of Wisconsin Carbone Cancer Center, and t
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Prices $5.5 Million Public Offering
2. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
3. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
4. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
5. Novelos Therapeutics Closes $2 Million Private Placement
6. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
9. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
10. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
11. Novelos Therapeutics Prices $5.4 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) ... year 2014 financial results on Tuesday, Jan. 27, 2015, after the ... by a conference call with the investment community at 2 p.m. ... A. Bradway , chairman and chief executive officer, and other members ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Infectious Disease Diagnostics Market by Product, Application, Technology, ... to their offering. , The infectious disease ... 7.9% to reach $18,156.2 million by 2019 from $12,422.8 ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... 5 ResMed Inc. (NYSE: RMD ), a ... medical equipment, announced today that it has acquired Laboratoires ... the Narval O.R.M.(TM), an innovative mandibular repositioning device (MRD) ... obstructive sleep apnea (OSA), especially for those with mild ...
... following letter is being released by CEL-SCI Corporation (NYSE ... Shareholders: , After FDA had communicated several weeks ago that ... proposed H1N1 treatment for hospitalized H1N1 patients, we have received ... mind, we have asked one of our outside collaborators, Ken ...
Cached Medicine Technology:ResMed Acquires Laboratoires Narval 2ResMed Acquires Laboratoires Narval 3CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5CEL-SCI Corporation Releases Letter to Shareholders 6CEL-SCI Corporation Releases Letter to Shareholders 7
(Date:1/22/2015)... (PRWEB) January 23, 2015 The U.S. ... R.Ph., DICVP, Director of Clinical Pharmacy Services at North ... the recipient of the 2015 Beal Award for Distinguished ... USP has relied on the contributions of volunteer experts ...
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... Initiative for Online Users to Learn about Each Candidate,s Health ... ... Miami, FL (PRWEB) August 28, 2008 -- ... provider search, announced today the launch of "HealthDecision ,08: Obama ...
... and March of Dimes Volunteer to take part in ... From Hell,s,Kitchen to a kitchen near you: Chef ... March of Dimes Signature Chef Auctions open to the ... of Dimes first national celebrity chef,spokesperson. In this role, ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced ... headcount by approximately 80% to 5 employees in,actions ... 2008 and October,2008. As a result of these ... its investigational agent for the,treatment of Clostridium difficile ...
... VaxGen,Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical ... the filing of its,quarterly report on Form 10-Q ... 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ), VaxGen ... and,investment securities as of June 30th, 2008, or ...
... make insulin-resistant proteins, study says , , WEDNESDAY, Aug. 27 (HealthDay ... to those in lean people, a new study shows. ... a group of researchers from the Temple University School of ... lean and six obese people. , They found significant differences ...
... study finds , , WEDNESDAY, Aug. 27 (HealthDay News) -- ... dose chemotherapy lived longer and better by adding the ... , The finding could make multiple myeloma, a cancer ... a lethal disease. And it would be particularly valuable ...
Cached Medicine News:Health News:HealthCare.com Launches HealthDecision '08: Obama and McCain on Health Care 2Health News:HealthCare.com Launches HealthDecision '08: Obama and McCain on Health Care 3Health News:Chef Rock to Rock Signature Chefs Auctions(R) Nationwide 2Health News:Replidyne Announces Restructuring of Operations 2Health News:VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment 2Health News:VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment 3Health News:Combination Therapy Helps to Combat Myeloma 2Health News:Combination Therapy Helps to Combat Myeloma 3
... AngioSpeed VH series, it is ... 2 independent C-arms and image ... dedicated for Cardiovascular and Angiography. ... perform the examinations for cerebral, ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Rubidium Rb 82 Generator. ,The only generator-based Positron Emission Tomography agent reimbursed for the evaluation of coronary artery disease....
Kit for the Preparation of Technetium Tc 99m Teboroxime...
Medicine Products: